USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
US COVID-19 Vaccines and Therapeutics Tracker—Market Insights and Trends, H1 2021
US COVID-19 Vaccines and Therapeutics Tracker—Market Insights and Trends, H1 2021
Agnostic Vaccine Platform Technology Enhancing Future Growth Potential of Participants in the Value Chain
30-Apr-2021
North America
$2,450.00
Special Price $1,837.50 save 25 %
Description
This study by Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the country’s vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines.
As of 31 March 2021, the US Food & Drug Administration granted Emergency Use Authorization to three vaccines manufactured respectively by Pfizer and BioNTech, Moderna, and Johnson & Johnson. Novavax and AstraZeneca vaccines are two other leading vaccine candidates expected to be approved for use in Q2 2021. Apart from vaccines, drugs are likely to play a critical role in treating individuals not responding to vaccines, not receiving vaccines, and who still contracted the virus despite vaccination.
Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization. Key topics covered in the study include:
• Key COVID-19 vaccines and therapeutics analysis
• COVID-19 vaccines supply chain and distribution analysis
• Snapshot of the US vaccination strategy
• Prospective analysis of COVID-19 becoming endemic
Author: Surbhi Gupta
Table of Contents
Growth Opportunities Fuel the Growth Pipeline Engine™
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the US COVID-19 Vaccines and Therapeutics Market
H1 2021 US Key Tracking Metrics
Executive Summary
Executive Summary (continued)
COVID-19 Vaccines Snapshot—Pipeline Analysis
COVID-19 Vaccines Snapshot—Vaccines Granted EUA
COVID-19 Vaccines Snapshot—Key Manufacturing Deals and Partnerships for the US Supply of Approved Vaccines
COVID-19 Vaccines Snapshot—Key Vaccine Candidates in Phase III
COVID-19 Therapeutics Snapshot—Current Global Treatments
COVID-19 Therapeutics Snapshot—Key Small Molecules in Phase III
COVID-19 Therapeutics Snapshot—Key mAbs in Phase III
COVID-19 Vaccines Manufacturing Supply Chain—Stages and Inputs
COVID-19 Vaccines Supply Chain—US Key Stakeholders
COVID-19 Vaccines Supply Chain from Factory to the Point of Use
US COVID-19 Vaccines Distribution Framework
Logistics Providers—Maintaining the Cold Chain to the Point of Use
Logistics Providers—Key Activities of Operation Warp Speed’s Logistics Partners
Central Distribution Hub—McKesson’s Role in Vaccines Distribution
Ancillary Supply Kits—Requisites for Different COVID-19 Vaccines
Scaling Up Syringes and Needles Manufacturing to Meet Vaccination Targets
US COVID-19 Vaccination Snapshot—By Vaccine Type
US COVID-19 Vaccination Snapshot—Administration Sites
US COVID-19 Vaccines Distribution Sites—Private Companies Fortifying Distribution Networks
US COVID-19 Vaccination Snapshot—Rollout in Key States
US COVID-19 Vaccination Snapshot—Successful Rollout Examples
Possible Factors of COVID-19 Becoming Endemic
Future of COVID-19 Vaccination—Seasonal Rollout Possibility
Growth Opportunity 1—Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021
Growth Opportunity 1—Agnostic Vaccine Platform Technology for Emerging Virus Variants and Future Infectious Disease Outbreaks, 2021 (continued)
Key Companies—Developing Next-generation COVID-19 Vaccines
Growth Opportunity 2—Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021
Growth Opportunity 2—Precise Syringes and Adequate Dry Ice Supply for Effective Mass Vaccination, 2021 (continued)
List of Exhibits
List of Exhibits (continued)
Legal Disclaimer
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Author | Surbhi Gupta |
| Industries | Healthcare |
| WIP Number | K613-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9562-B1,9568-B1,9611-B1,9627-B1 |